Publications by authors named "P E Rasmussen"
Currently, there are limited therapeutic options for patients with non-active secondary progressive multiple sclerosis. Therefore, real-world studies have investigated differences between patients with relapsing-remitting multiple sclerosis, non-active secondary progressive multiple sclerosis and active secondary progressive multiple sclerosis. Here, we explore patterns and predictors of transitioning between these phenotypes.
View Article and Find Full Text PDFPeople with intellectual disabilities (IDs) face health issues and barriers to physical activity. Health promotion programmes targeting this group are often short-term. Few programmes have been designed for people with IDs who live in supported housing staffed by social care workers (SCWs).
View Article and Find Full Text PDFBackground: Moyamoya disease (MMD) is a rare cerebrovascular disorder marked by internal carotid artery narrowing, collateral neovascularization, and symptomatic cerebral ischemia. Select patients can benefit from direct bypass (STA-MCA bypass) by restoring blood flow to hypoperfused territories. Symptomatic contralateral stroke (CS) following STA-MCA bypass is a devastating, poorly understood complication.
View Article and Find Full Text PDFIntroduction: Anatomic factors that predict outcomes following basal ganglia intracranial hemorrhage (bgICH) evacuation are poorly understood. Given the compact neuroanatomic organization of the basal ganglia, we hypothesized that bgICH spatial representation could predict postoperative functional outcomes.
Methods: Patients undergoing minimally invasive surgical bgICH evacuation between 2013 and 2024 at one center were retrospectively reviewed.
Article Synopsis
- Teriflunomide, a medication for multiple sclerosis (MS), is linked to a higher risk of developing hypertension compared to another MS treatment, dimethyl fumarate.
- A study involving nearly 5,000 adult patients over 10 years showed that hypertension events occurred significantly more in those on teriflunomide (40.6 per 1000 person-years) than in those on dimethyl fumarate (13.1 per 1000 person-years).
- The findings indicate that patients on teriflunomide are 2.8 times more likely to develop hypertension, with a concerning "number needed to harm" of 16 at 3 years and 9 at 5 years.